Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 13/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16059491 | 1.00 | EPHX1 (0.40) | EPHX1GAAKDM4EALDH1A1NAMPT | |
| SCHEMBL16059493 | 1.00 | EPHX1 (0.40) | EPHX1GAAKDM4EALDH1A1NAMPT | |
| SCHEMBL16059507 | 0.90 | EPHX1 (0.49) | EPHX1GAAKDM4EALDH1A1EPHX2 | |
| SCHEMBL16058731 | 0.80 | EPHX1 (0.53) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL22635693 | 0.77 | EPHX1 (0.59) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL16060491 | 0.77 | EPHX1 (0.65) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL10254622 | 0.75 | EPHX1 (0.68) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL16059861 | 0.74 | TP53 (0.49) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL8368741 | 0.73 | CHRM4 (0.39) | EPHX1KDM4EALDH1A1NAMPTEPHX2 | |
| SCHEMBL12988087 | 0.72 | GSTO1 (0.34) | EPHX1ALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9133183-B2 | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | EPHX1 2730/4885GAA 1789/4885KDM4E 821/4885 |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | EPHX1 2730/4885GAA 1789/4885KDM4E 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.